Karl Albert Brokstad
Overview
Explore the profile of Karl Albert Brokstad including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
25
Citations
621
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Ekanger C, Dinesh Kumar N, Koutstaal R, Zhou F, Beukema M, Waldock J, et al.
Front Immunol
. 2025 Feb;
16:1532144.
PMID: 39981254
Introduction: Complex respiratory models, including air-liquid interface (ALI) transwell cultures and airway organoids, have emerged as promising tools for studying human respiratory virus infections. These models address several limitations of...
2.
Bansal A, Trieu M, Eriksson E, Zhou F, McVernon J, Brokstad K, et al.
Sci Rep
. 2025 Feb;
15(1):4705.
PMID: 39922967
To protect healthcare workforce during the COVID-19 pandemic, rigorous efforts were made to reduce infection rates among healthcare workers (HCWs), especially prior to vaccine availability. This study aimed to investigate...
3.
Hu H, Zhou F, Ma X, Brokstad K, Kolmar L, Girardot C, et al.
PNAS Nexus
. 2025 Jan;
4(1):pgaf006.
PMID: 39867668
Here, we present Link-Seq, a highly efficient droplet microfluidic method for combined sequencing of antibody-encoding genes and the transcriptome of individual B cells at large scale. The method is based...
4.
Bredholt G, Saevik M, Soyland H, Ueland T, Zhou F, Pathirana R, et al.
Vaccine X
. 2024 Oct;
20:100564.
PMID: 39403561
Objectives: Booster COVID-19 vaccinations are used to protect the elderly, a group vulnerable to severe disease. We compared humoral and cellular immunity in older versus younger adults up to eight...
5.
Petrovic A, Bueide I, Tveit K, Hallaraker H, Bjorndal B, Holmes T, et al.
Front Immunol
. 2023 Sep;
14:1128986.
PMID: 37744329
Background: Psoriasis is a chronic immune-mediated skin disease with systemic inflammation and comorbidities. Although the disease severity may vary over time, many patients suffer from mild to moderate disease. Often...
6.
Bansal A, Trieu M, Mohn K, Madsen A, Olofsson J, Sandnes H, et al.
Front Public Health
. 2023 Aug;
11:1164326.
PMID: 37546332
Background: Preventing infection in healthcare workers (HCWs) is crucial for protecting healthcare systems during the COVID-19 pandemic. Here, we investigated the seroepidemiology of SARS-CoV-2 in HCWs in Norway with low-transmission...
7.
Hansen L, Brokstad K, Bansal A, Zhou F, Bredholt G, Onyango T, et al.
Vaccine X
. 2023 Jan;
13:100262.
PMID: 36643855
Objectives: Elderly are an understudied, high-risk group vulnerable to severe COVID-19. We comprehensively analyzed the durability of humoral and cellular immune responses after BNT162b2 vaccination and SARS-CoV-2 infection in elderly...
8.
Ertesvag N, Sakkestad S, Zhou F, Hoff I, Kristiansen T, Jonassen T, et al.
Viruses
. 2022 Aug;
14(8).
PMID: 36016378
Persistent fever after SARS-CoV-2 infection in rituximab-treated patients has been reported. Due to reduced sensitivity in conventional sampling methods and unspecific symptoms in these patients, distinguishing between low-grade viral replication...
9.
Ertesvag N, Cox R, Lartey S, Mohn K, Brokstad K, Trieu M
NPJ Vaccines
. 2022 Jun;
7(1):67.
PMID: 35750781
History of influenza A/H3N2 exposure, especially childhood infection, shape antibody responses after influenza vaccination and infection, but have not been extensively studied. We investigated the breadth and durability of influenza...
10.
Ertesvag N, Xiao J, Zhou F, Ljostveit S, Sandnes H, Lartey S, et al.
Commun Med (Lond)
. 2022 May;
2:36.
PMID: 35603265
Background: Evaluation of susceptibility to emerging SARS-CoV-2 variants of concern (VOC) requires rapid screening tests for neutralising antibodies which provide protection. Methods: Firstly, we developed a receptor-binding domain-specific haemagglutination test...